Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 13/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.36 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17746989 | 0.88 | NOD1 (0.65) | NOD1SLC6A5 | |
| SCHEMBL17746988 | 0.88 | NOD1 (0.65) | NOD1SLC6A5 | |
| SCHEMBL20009572 | 0.86 | GNPAT (0.54) | NOD1GNPATFOLH1RIMKLANAALAD2 | |
| SCHEMBL20009636 | 0.85 | KMT2A (0.39) | NOD1HDAC2 | |
| SCHEMBL26113216 | 0.82 | NOD1 (0.49) | NOD1SLC6A5GNPATFOLH1RIMKLA | |
| SCHEMBL17746971 | 0.82 | NOD1 (0.49) | NOD1SLC6A5GNPATFOLH1RIMKLA | |
| SCHEMBL17746981 | 0.82 | NOD1 (0.49) | NOD1SLC6A5GNPATFOLH1RIMKLA | |
| SCHEMBL17746969 | 0.82 | NOD1 (0.49) | NOD1SLC6A5GNPATFOLH1RIMKLA | |
| SCHEMBL17746979 | 0.82 | NOD1 (0.49) | NOD1SLC6A5GNPATFOLH1RIMKLA | |
| SCHEMBL17481432 | 0.81 | NOD1 (0.63) | NOD1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086793-A1 | IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086793-A1 | IMMUNOMODULATORS | CD74, ICOS, HAVCR2 | NOD1 447/4885SLC6A5 4762/4885GNPAT 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.